| First Author | Huang TY | Year | 2016 |
| Journal | J Neurosci | Volume | 36 |
| Issue | 30 | Pages | 7996-8011 |
| PubMed ID | 27466343 | Mgi Jnum | J:234625 |
| Mgi Id | MGI:5790507 | Doi | 10.1523/JNEUROSCI.0206-16.2016 |
| Citation | Huang TY, et al. (2016) SNX27 and SORLA Interact to Reduce Amyloidogenic Subcellular Distribution and Processing of Amyloid Precursor Protein. J Neurosci 36(30):7996-8011 |
| abstractText | Proteolytic generation of amyloidogenic amyloid beta (Abeta) fragments from the amyloid precursor protein (APP) significantly contributes to Alzheimer's disease (AD). Although amyloidogenic APP proteolysis can be affected by trafficking through genetically associated AD components such as SORLA, how SORLA functionally interacts with other trafficking components is yet unclear. Here, we report that SNX27, an endosomal trafficking/recycling factor and a negative regulator of the gamma-secretase complex, binds to the SORLA cytosolic tail to form a ternary complex with APP. SNX27 enhances cell surface SORLA and APP levels in human cell lines and mouse primary neurons, and depletion of SNX27 or SORLA reduces APP endosome-to-cell surface recycling kinetics. SNX27 overexpression enhances the generation of cell surface APP cleavage products such as soluble alpha-APP C-terminal fragment (CTFalpha) in a SORLA-dependent manner. SORLA-mediated Abeta reduction is attenuated by downregulation of SNX27. This indicates that an SNX27/SORLA complex functionally interacts to limit APP distribution to amyloidogenic compartments, forming a non-amyloidogenic shunt to promote APP recycling to the cell surface. SIGNIFICANCE STATEMENT: Many genes have been identified as risk factors for Alzheimer's disease (AD), and a large proportion of these genes function to limit production or toxicity of the AD-associated amyloid beta (Abeta) peptide. Whether and how these genes precisely operate to limit AD onset remains an important question. We identify binding and trafficking interactions between two of these factors, SORLA and SNX27, and demonstrate that SNX27 can direct trafficking of SORLA and the Abeta precursor APP to the cell surface to limit the production of Abeta. Diversion APP to the cell surface through modulation of this molecular complex may represent a complimentary strategy for future development in AD treatment. |
